Beam Therapeutics (BEAM) Other Accumulated Expenses (2020 - 2026)

Beam Therapeutics (BEAM) has 7 years of Other Accumulated Expenses data on file, last reported at $9.2 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 166.91% year-over-year to $9.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.2 million (up 166.91% YoY) and the FY2025 annual result came in at $2.0 million, down 74.59% from the prior year.
• Other Accumulated Expenses advanced to $9.2 million in Q1 2026 per BEAM's latest filing, from $2.0 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $28.6 million in Q4 2023 and bottomed at $2.0 million in Q4 2025.
• The 5-year median for Other Accumulated Expenses is $7.8 million (2024), against an average of $10.2 million.
• The widest annual swing landed in 2024, when Other Accumulated Expenses jumped 212.95%; it then plunged 90.49% in 2025.
• Tracing BEAM's Other Accumulated Expenses over 5 years: stood at $12.3 million in 2022, then jumped by 133.58% to $28.6 million in 2023, then tumbled by 72.73% to $7.8 million in 2024, then slumped by 74.59% to $2.0 million in 2025, then jumped by 361.21% to $9.2 million in 2026.
• Per Business Quant, the three latest BEAM Other Accumulated Expenses figures stand at $9.2 million (Q1 2026), $2.0 million (Q4 2025), and $2.7 million (Q3 2025).

Peer Comparison